Fig. 6

Tumor cells-derived sEVs miRNAs contribute to plasma sEVs miRNAs signature in AOC patients A: The 4-miRNA expressions in tumor tissue between two groups were verified by Taqman qRT-PCR (R0, n = 20; non-R0, n = 30). B: The 4-miRNA expressions in sEVs derived from primary tumor tissue (PTT, n = 6), metastatic tumor tissue (MTT, n = 6), adjacent tissue (AT, n = 6), or non-tumor tissue (NTT, n = 6) via Taqman qRT-PCR. C: Representative western blots of cell-type-specific protein in primary tumor tissue sEVs (n = 6); D: Taqman qRT-PCR analysis of 4-miRNA in different cell-source sEVs separated from primary tumor tissue (n = 3); E: Taqman qRT-PCR analysis of 4-miRNA in plasma different cell-source sEVs captured by magnetic beads sorting system (n = 6); EpCAM was chosen as epithelial ovarian cancer cells marker; FAP as cancer-associated fibroblasts marker; CD31 as endothelial cells marker; CD45 as tumor-infiltrating immune cells and leukocytes marker; CD235a as erythrocytes marker. F: The comparison of model index score between R0 (n = 82) or non-R0 (n = 102) patients and benign pelvic diseases (BPD, n = 21), early-stage ovarian cancer with FIGO I or II (ESOC, n = 20), and advanced colorectal cancer patients (ACC, n = 22). G: The relative expression levels of miR-320a-3p, miR-378a-3p, miR-1307-3p, let-7d-3p were detected from total plasma, plasma sEVs, and plasma sEVs pretreating with RNase A. miRNA, microRNA; R0, advanced ovarian cancer with no residual disease; non-R0, advanced ovarian cancer with any residual disease; sEVs, small extracellular vesicles; AOC, advanced ovarian cancer; *P < 0.05; ** < 0.01; *** < 0.001; **** < 0.0001 (unpaired t-test)